CEO of Cash-Poor MDRNA Says Money-Making Deals On Horizon, But Stays Mum on Specifics | GenomeWeb
Just months after a sweeping corporate reorganization, MDRNA’s top official last week tried to assure investors that the company is poised to hit a number of key financial goals — even as it faces a dwindling cash supply and a stock price that has dropped almost 90 percent since the beginning of the year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.